Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Dexcom (DXCM) EBIAT (2016 - 2025)

Dexcom (DXCM) has disclosed EBIAT for 16 consecutive years, with $267.3 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIAT rose 76.2% to $267.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $836.3 million, a 45.14% increase, with the full-year FY2025 number at $836.3 million, up 45.14% from a year prior.
  • EBIAT was $267.3 million for Q4 2025 at Dexcom, down from $283.8 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $283.8 million in Q3 2025 to a low of $42.8 million in Q4 2021.
  • A 5-year average of $127.2 million and a median of $110.6 million in 2023 define the central range for EBIAT.
  • Peak YoY movement for EBIAT: plummeted 89.59% in 2021, then surged 201.23% in 2024.
  • Dexcom's EBIAT stood at $42.8 million in 2021, then skyrocketed by 114.49% to $91.8 million in 2022, then soared by 179.19% to $256.3 million in 2023, then crashed by 40.81% to $151.7 million in 2024, then surged by 76.2% to $267.3 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's EBIAT are $267.3 million (Q4 2025), $283.8 million (Q3 2025), and $179.8 million (Q2 2025).